Literature DB >> 8500476

Antibody response to a major human Pneumocystis carinii surface antigen in patients without evidence of immunosuppression and in patients with suspected atypical pneumonia.

B Lundgren1, M Lebech, K Lind, J O Nielsen, J D Lundgren.   

Abstract

IgG and IgM antibodies to a purified human Pneumocystis carinii surface antigen (gp95) were measured in 694 serum specimens from two different population groups using an EIA technique. In a population of 441 patients with no evidence of immunosuppression, the percentage of persons positive for IgG antibodies to gp95 was significantly lower in the age group 1 to 9 years (30%, 23/77) compared to persons 10 to 19 years old (56%, 49/88). In the age group 1 to 14 years there was a significant correlation between the percentage of persons with IgG antibodies to gp95 and age. In 106 consecutive patients under evaluation due to atypical pneumonia, 76 patients showed no change in the titre of antibodies to Legionella spp. or Mycoplasma pneumoniae in two consecutive serum samples. Three of these 76 patients (4%) demonstrated an increase in the level of IgG antibodies to gp95 in the paired samples. One of these patients had a verified Pneumocystis carinii pneumonia, and the two others were elderly men in whom no microbiological diagnosis of the pneumonia was established. Thus, it is concluded that IgG antibodies to gp95 develop in the majority of nonimmunosuppressed persons before the age of 13. Furthermore, Pneumocystis carinii pneumonia should be considered in the differential diagnosis in patients suspected of having atypical pneumonia.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8500476     DOI: 10.1007/BF01967583

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  17 in total

Review 1.  Pneumocystis carinii pneumonia (PCP).

Authors:  G Y Lipschik; H Masur
Journal:  Prog Clin Parasitol       Date:  1991

2.  Antibody responses to a major Pneumocystis carinii antigen in human immunodeficiency virus-infected patients with and without P. carinii pneumonia.

Authors:  B Lundgren; J D Lundgren; T Nielsen; L Mathiesen; J O Nielsen; J A Kovacs
Journal:  J Infect Dis       Date:  1992-06       Impact factor: 5.226

3.  Analyses of rat Pneumocystis carinii antigens recognized by human and rat antibodies by using western immunoblotting.

Authors:  D C Graves; S J McNabb; M A Worley; T D Downs; M H Ivey
Journal:  Infect Immun       Date:  1986-10       Impact factor: 3.441

4.  Serologic responses to Pneumocystis carinii antigens in health and disease.

Authors:  S L Peglow; A G Smulian; M J Linke; C L Pogue; S Nurre; J Crisler; J Phair; J W Gold; D Armstrong; P D Walzer
Journal:  J Infect Dis       Date:  1990-02       Impact factor: 5.226

5.  Detection of specific antibody by enzyme-linked immunosorbent assay and antigenemia by counterimmunoelectrophoresis in humans infected with Pneumocystis carinii.

Authors:  S E Maddison; G V Hayes; S B Slemenda; L G Norman; M H Ivey
Journal:  J Clin Microbiol       Date:  1982-06       Impact factor: 5.948

6.  A comparison of the antigenic characteristics of rat and human Pneumocystis carinii by immunoblotting.

Authors:  P D Walzer; M J Linke
Journal:  J Immunol       Date:  1987-04-01       Impact factor: 5.422

7.  Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children.

Authors:  L L Pifer; W T Hughes; S Stagno; D Woods
Journal:  Pediatrics       Date:  1978-01       Impact factor: 7.124

8.  An enzyme-linked immunosorbent assay for detection of IgM antibodies to Toxoplasma gondii: use for diagnosis of acute acquired toxoplasmosis.

Authors:  Y Naot; J S Remington
Journal:  J Infect Dis       Date:  1980-11       Impact factor: 5.226

9.  Purification and characterization of a major human Pneumocystis carinii surface antigen.

Authors:  B Lundgren; G Y Lipschik; J A Kovacs
Journal:  J Clin Invest       Date:  1991-01       Impact factor: 14.808

10.  Identification of antigens and antibodies specific for Pneumocystis carinii.

Authors:  J A Kovacs; J L Halpern; J C Swan; J Moss; J E Parrillo; H Masur
Journal:  J Immunol       Date:  1988-03-15       Impact factor: 5.422

View more
  8 in total

1.  Expression, structure, and location of epitopes of the major surface glycoprotein of Pneumocystis carinii f. sp. carinii.

Authors:  M J Linke; S M Sunkin; R P Andrews; J R Stringer; P D Walzer
Journal:  Clin Diagn Lab Immunol       Date:  1998-01

2.  Transmission of Pneumocystis carinii from patients to hospital staff.

Authors:  B Lundgren; K Elvin; L P Rothman; I Ljungström; C Lidman; J D Lundgren
Journal:  Thorax       Date:  1997-05       Impact factor: 9.139

3.  Characterization of major surface glycoprotein genes of human Pneumocystis carinii and high-level expression of a conserved region.

Authors:  Q Mei; R E Turner; V Sorial; D Klivington; C W Angus; J A Kovacs
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

4.  Primary pneumocystis infection in infants hospitalized with acute respiratory tract infection.

Authors:  Hans Henrik Larsen; Marie-Louise von Linstow; Bettina Lundgren; Birthe Høgh; Henrik Westh; Jens D Lundgren
Journal:  Emerg Infect Dis       Date:  2007-01       Impact factor: 6.883

5.  Molecular characterization of clustered variants of genes encoding major surface antigens of human Pneumocystis carinii.

Authors:  T R Garbe; J R Stringer
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

6.  Geographical variation in serological responses to recombinant Pneumocystis jirovecii major surface glycoprotein antigens.

Authors:  K Daly; J Koch; N Respaldiza; C de la Horra; M A Montes-Cano; F J Medrano; J M Varela; E J Calderon; P D Walzer
Journal:  Clin Microbiol Infect       Date:  2009-03-21       Impact factor: 8.067

7.  Healthcare worker occupation and immune response to Pneumocystis jirovecii.

Authors:  Renuka Tipirneni; Kieran R Daly; Leah G Jarlsberg; Judy V Koch; Alexandra Swartzman; Brenna M Roth; Peter D Walzer; Laurence Huang
Journal:  Emerg Infect Dis       Date:  2009-10       Impact factor: 6.883

8.  Enzyme-linked immunosorbent assay and serologic responses to Pneumocystis jiroveci.

Authors:  Kieran R Daly; Judy Koch; Linda Levin; Peter D Walzer
Journal:  Emerg Infect Dis       Date:  2004-05       Impact factor: 6.883

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.